BMS comment on the RCOG/BSGE/BSGC guidance on heavy menstrual bleeding
BMS statement on the RCOG/BSGE/BGCS document on the management of irregular menstrual bleeding/postmenopausal bleeding.
HRT prescribing alert during Covid 19
A joint statement from the BMS, RCOG, RCGP and FSRH.
Extended use of contraceptive implant and Mirena IUS
FSRH has advised that the use of the Mirena IUS can be extended up to 6 years for contraception.
New Climacteric article on HRT and breast cancer
An article by J. C. Stevenson & R. D. T. Farmer entitled 'HRT and breast cancer: a million women ride again' was published online on 11 March 2020 in the Climacteric.
Evorel: UK Stock update
Please see the latest update with regards to Evorel stock.
Welcome Hugo Pedder
We are pleased to announce that Hugo Pedder has been co-opted onto the BMS Medical Advisory Council as Statistical advisor to the BMS.
Availability of menopausal hormone therapy products worldwide
The menopause transition can have a significant impact on many women, with more than 75 % experiencing menopausal symptoms, and a quarter describing severe symptoms.
RCOG, BMS, FSRH statement on HRT and contraceptive supply
The RCOG, BMS and FSRH have issued a press release regarding the HRT and contraceptive shortages.
Concerns over new ‘menopause delay’ procedure
Melanie Davies, chair of Fertility Preservation UK and BMS medical advisory council member raises concern over a new medical procedure that claims to allow women to delay the onset of the menopause by over a decade.
British Menopause Society further update on HRT supply shortages (27th January 2020)
The British Menopause Society has issued this further update on the current availability of HRT products to provide guidance to BMS members and clinical practitioners in response to the ongoing HRT shortages.